Top

Annals of Surgical Oncology

Published in:

01-01-2012 | Gastrointestinal Oncology

HIPEC for Peritoneal Carcinomatosis: Does an Associated Urologic Procedure Increase Morbidity?

Authors: C. Honoré, MD, A. Souadka, MD, D. Goéré, MD, F. Dumont, MD, F. Deschamps, MD, D. Elias, MD, PhD

Published in: Annals of Surgical Oncology | Issue 1/2012

Abstract

Purpose

To report the incidence of urinary tract procedures performed during complete cytoreductive surgery (CCRS) plus intraperitoneal chemotherapy, and to report the types of procedure, specific morbidity, risk factors, and treatment.

Methods

Data were extracted from a prospective database of patients with malignant peritoneal disease treated with CCRS plus intraperitoneal chemotherapy who had undergone a resection or suture of the bladder, ureter, or kidney. Patients were eligible whatever the tumor origin.

Results

Between 1994 and 2010, among the 598 patients treated with CCRS plus intraperitoneal chemotherapy, 48 (8%) had undergone a resection or suture in the urinary tract. Procedures included 4 nephrectomies, 19 partial cystectomies, 8 surgically repaired bladder injuries, and 18 ureteral resections. Postoperative mortality was 4% and morbidity was 41%. Specific complications included 6 urinary fistulas (12%), two among the 27 bladder sutures (7%) and four among the 18 ureteral sutures (22%) (P = NS). In the multivariate analysis, the risk factors for urinary fistula were severe preoperative malnutrition (P = 0.05, relative risk [RR] = 7.3) and extensive peritoneal disease (peritoneal cancer index ≥20, P = 0.05, RR = 8.3). Urinary fistulas had been treated nonsurgically in most of the cases.

Conclusions

Associated urinary tract procedures had occurred in 8% of the cases but did not greatly increase morbidity. Therefore, urinary tract involvement or injury are not contraindications to performing CCRS plus intraperitoneal chemotherapy. Fistulas had complicated only 12% of urinary sutures, mainly in cases of malnutrition or extensive peritoneal disease.

Sugarbaker PH. Surgical management of carcinomatosis from colorectal cancer. Clin Colon Rectal Surg. 2005;18:190–203.PubMedCrossRef

Esquivel J, Elias D, Barrati D, et al. Consensus statement on the loco regional treatment of colorectal cancer with peritoneal dissemination. J Surg Oncol. 2008;98:263–7.PubMedCrossRef

Elias D, Gilly F, Boutitie F, et al. Peritoneal colorectal carcinomatosis with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2010;28:63–8.PubMedCrossRef

Sugarbaker PH. A perspective on clinical research strategies in carcinoma of the large bowel. World J Surg. 1991;15:609–16.PubMedCrossRef

Smeenk RM, Bex A, Verwaal VJ, et al. Pseudomyxoma peritonei and the urinary tract: involvement and treatment related complications. J Surg Oncol. 2006;93:20–3.PubMedCrossRef

Sugarbaker PH. Peritoneal carcinomatosis: natural history and rational therapeutic interventions using intraperitoneal chemotherapy. Cancer Treat Res. 1996;81:149–68.PubMedCrossRef

Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649–55.PubMedCrossRef

Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359–74.PubMedCrossRef

Elias D, Blot F, El Otmany A, et al. Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. Cancer. 2001;1;92:71–6.CrossRef

10.

Jacquet P, Averbach A, Stephens AD, et al. Heated intraoperative intraperitoneal mitomycin C and early postoperative intraperitoneal 5-fluorouracil: pharmacokinetic studies. Oncology. 1998;55:130–8.PubMedCrossRef

11.

Elias D, Bonnay M, Puizillou JM, et al. Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol. 2002;13:267–72.PubMedCrossRef

12.

Sugarbaker PH, Graves T, DeBruijn EA, et al. Early postoperative intraperitoneal chemotherapy as an adjuvant therapy to surgery for peritoneal carcinomatosis from gastrointestinal cancer: pharmacological studies. Cancer Res. 1990;15:5790–4.

13.

Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.PubMedCrossRef

14.

Clavien PA, Barkun J, de Oliveira ML, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250:187–96.PubMedCrossRef

15.

Glehen O, Osinsky D, Cotte E, et al. Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures. Ann Surg Oncol. 2003;10:863–9.PubMedCrossRef

16.

Kusamura S, Younan R, Baratti D, et al. Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion: analysis of morbidity and mortality in 209 peritoneal surface malignancies treated with closed abdomen technique. Cancer. 2006;106:1144–53.PubMedCrossRef

17.

Stephens AD, Alderman R, Chang D, et al. Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique. Ann Surg Oncol. 1999;6:790–6.PubMedCrossRef

18.

Yan TD, Links M, Fransi S, et al. Learning curve for cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal surface malignancy—a journey to becoming a nationally funded peritonectomy center. Ann Surg Oncol. 2007;14:2270–80.PubMedCrossRef

19.

Corish CA, Kennedy NP. Protein-energy undernutrition in hospital in-patients. Br J Nutr. 2000;83:575–91.PubMedCrossRef

20.

Mariette C, Alves A, Benoist S, Bretagnol F, Mabrut JY, Slim K. [Perioperative care in digestive surgery. Guidelines for the French society of digestive surgery (SFCD)] (in French). Ann Chir. 2005;130:108–24.PubMedCrossRef

21.

Glehen O, Gilly FN, Boutitie F, et al. the French Surgical Association. Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1290 patients. Cancer. 2010;116:5608–18.PubMedCrossRef

Title: HIPEC for Peritoneal Carcinomatosis: Does an Associated Urologic Procedure Increase Morbidity?
Authors: C. Honoré, MD
A. Souadka, MD
D. Goéré, MD
F. Dumont, MD
F. Deschamps, MD
D. Elias, MD, PhD
Publication date: 01-01-2012
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 1/2012
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-011-1820-2

At a glance: The STEP trials

Springer Medicine

HIPEC for Peritoneal Carcinomatosis: Does an Associated Urologic Procedure Increase Morbidity?

Abstract

Purpose

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2012

Diagnostic Accuracy of Surgeon-Performed Ultrasound-Guided Fine-Needle Aspiration of Thyroid Nodules

MRI Versus Breast-Specific Gamma Imaging (BSGI) in Newly Diagnosed Ductal Cell Carcinoma-in-situ: A Prospective Head-to-Head Trial

Timing of Preoperative Pharmacoprophylaxis for Pancreatic Surgery Patients: A Venous Thromboembolism Reduction Initiative

Preservation of the Pyloric Ring Has Little Value in Surgery for Pancreatic Head Cancer: A Comparative Study Comparing Three Surgical Procedures

Reduction/Prevention of Lower Extremity Lymphedema after Pelvic and Para-aortic Lymphadenectomy for Patients with Gynecologic Malignancies

Survivin-Mediated Cancer Cell Migration Through GRP78 and Epithelial-Mesenchymal Transition (EMT) Marker Expression in Mahlavu Cells